急性肺损伤是一种炎症性肺病，其特征是炎症细胞浸润到肺组织和促炎介质的过度产生。在患者中表现为急性呼吸窘迫综合征，重症患者的病死率高达30%，严重威胁人类生命健康。目前，国内外对白芍的化学成分及药理作用研究较深入，发现白芍中含有多种化学成分，且药理作用显著。然而，目前对于白芍通过配伍策略治疗急性肺损伤的研究进展缺乏系统性的整合与评述。从单味活性成分作用机制与核心药对配伍增效减毒机制2个维度进行系统性梳理，为白芍配伍开发安全有效的急性肺损伤防治策略提供更全面的理论依据和研究思路。未来应着重推进高质量临床试验验证其疗效，并探索新型递药系统以提升活性成分的生物利用度与靶向性。

Acute lung injury is an inflammatory lung disease characterized by the infiltration of inflammatory cells into lung tissue and the excessive production of pro-inflammatory mediators. It manifests as acute respiratory distress syndrome in patients. The fatality rate of severe patients is as high as 30%, seriously threatening human life and health. At present, both at home and abroad, in-depth research has been conducted on the chemical components and pharmacological effects of Baishao (Paeoniae Radix Alba). It has been found that Paeoniae Radix Alba contains a variety of chemical components and has significant pharmacological effects. However, there is a lack of systematic integration and review of the research progress on the treatment of acute lung injury with Paeoniae Radix Alba through compatibility strategies. A systematic review was conducted from two dimensions: the mechanism of action of individual active ingredients and the mechanism of enhancing efficacy and reducing toxicity in the compatibility of core drugs, providing a more comprehensive theoretical basis and research ideas for the development of safe and effective prevention and treatment strategies for acute lung injury through the compatibility of Paeoniae Radix Alba. In the future, efforts should be focused on promoting high-quality clinical trials to verify its efficacy and exploring new drug delivery systems to enhance the bioavailability and targeting of active ingredients.

R285

国家自然科学基金资助项目(82374300)